New Biotechnological Platform for Cancer Treatment Testing

An international research team, with significant participation from the Technical University of Denmark (DTU), has developed a new biotechnological platform. This platform aims to accelerate and reduce the cost of testing and understanding advanced cancer treatments.

Leveraging Yeast Surface Display

Published in Nature Communications, the study introduces a yeast surface display technology. This innovative method utilizes modified yeast to simulate human cancer cells, allowing researchers to examine how patients' immune cells, known as CAR T cells (Chimeric Antigen Receptor T cells), react to various cancer antigens.

Professor Sine Reker Hadrup from DTU Health Technology stated that the engineered yeast cells accurately mimicked real cancer cells, activating CAR T cells effectively. The precision, speed, and cost-effectiveness of this platform enable large-scale testing of immunotherapies at an unprecedented pace, potentially leading to safer and more targeted cancer treatments.

Broader Impact and Applications

While not immediately altering current treatments, the platform is expected to have a long-term impact by:

• Enabling faster assessment of promising CAR T variants.
• Identifying entry points for treating solid tumors, which have been traditionally challenging.

CAR T cell therapy involves genetically reprogramming a patient's own T cells to recognize and attack cancer cells. This potent treatment is particularly effective for blood cancer, but its development is complex, risky, and expensive. The new platform aims to make this development process more predictable.

The Yeast Model Explained

Researchers genetically modified common yeast strains to express human cancer antigens on their cell surface. This innovative approach allows the yeast surface to function as a biological test screen. The yeast produces and displays specific antigens, enabling researchers to expose these strains to CAR T cells and measure their response.

This method is more economical and faster than cultivating human cancer cells or employing advanced nanotechnological systems. The researchers reported that the yeast-based models perform as effectively as, and in some cases more robustly than, traditional cancer cell lines.

Key Advantages for Research

According to DTU researchers Professor Sine R. Hadrup, Marcus Deichmann, and Emil D. Jensen, the platform facilitates:

• Rapid and systematic testing of multiple antigens.
• Improved understanding of why certain CAR T designs are more effective.
• Prediction of CAR T cell responses to cancer cells' immune evasion strategies.

Given that yeast grows quickly and can be adapted within days, this technology provides a flexible screening tool accessible to research environments of all sizes, contributing to the faster development of improved CAR T therapies.